The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of ...
The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available ...
The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...
2don MSN
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...
For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global ...
(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.
The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized ...
Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no cure for debilitating neurological conditions like ...
The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in ...
BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s ...
The FDA approved adaptive deep brain stimulation (DBS) technology (BrainSense adaptive DBS and BrainSense electrode ...
Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results